investigational product discontinuation
reason drug discontinuation
text
other reason for drug discontinuation
text
PGx-Pharmacogenetic Research
consent for pgx-pharmacogenetic research
boolean
Informed consent if yes
date
if no in the item "consent for PGx-pharmacogenetic research", pick one reason. If Z = other, specify in the "other reason, specify" item.
text
blood sample collection dna pharmacogenetic research
boolean
date sample taken pharmacogenetic research
date
Withdrawal of consent
boolean
Blood sample destruction
boolean
Please specify if "Has a request been made for sample destruction?"=Yes
text
Concomitant Medications
If Yes to Concominant Medication
Drug name
text
Route
text
Unit Dose
float
Units
text
Frequency concomitant medication
text
Where appropriate, medical conditions should be recorded in the Significant Medical/Surgical History and Physical Examination section, utilizing the same terminology. Prior chemotherapy, biological, and immunotherapy should be recorded on pages 4 and 5. Record PM for prophylactic treatment with the Medical Condition for prophylactically administered medications.
text
Start Date
date
Taken Prior to Study?
boolean
End Date
date
Ongoing medication
boolean
NON-SERIOUS ADVERSE EVENTS (AE)
If Yes, record details below.
text
Record details of any new non-serious adverse events / serious adverse events observed or reported by the subject or any changes to ongoing non-serious adverse events in the appropriate Non-Serious Adverse Events / Serious Adverse Events section.
text
NON-SERIOUS ADVERSE EVENTS (AE)
Enter only the diagnosis (if known); otherwise enter sign or symptom. If a diagnosis subsequently becomes available, then this should be entered and the sign or symptom crossed out, initialled and dated by the investigator.
text
Record the start date of the first occurrence of the AE.
date
All AEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the AE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the AE was ongoing at the time of death, but was not the cause of death.
integer
Record the end date. This is the date the AE Recovered/Resolved. If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the AE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.
date
Maximum Toxicity
text
Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing).
text
Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’.
text
It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.
text
Serious adverse event
Section 1
autopsy
boolean
Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page.
boolean
Record the start date of the first occurrence of the SAE.
date
All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death.
integer
Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/ Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.
date
Maximum Toxicity
text
Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced =Dose is reduced for one or more investigational product(s). Dose increased =Dose increased for one or more investigational product(s). Dose not changed=Investigational product(s) continues even though an adverse event has occurred. Dose interrupted=Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Not applicable=Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s).
text
Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’.
boolean
It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.
boolean
Section 2: Seriousness
SAE results in death
boolean
SAE is life-threatening
boolean
SAE requires hospitalisation
boolean
SAE results in disability/incapacity
boolean
Congenital anomaly/birth defect
boolean
Óther SAE
boolean
Other SAE specificationn
text
SECTION 3 Demography Data
SECTION 4
Section 5
Possible Causes of SAE Other Than Investigational Product(s)
text
If
text
If "Concomitant medication(s)", specify:
text
If "Other", specify:
text
SECTION 6: RELEVANT Medical Conditions
Relevant Medical Conditions
text
Date of onset
date
continuation SAE
text
Date of Last Occurrence
date
SECTION 7 Other RELEVANT Risk Factors
Risk Factors substance use disorder occupational hazard
text
SECTION 8 RELEVANT Concomitant Medications
Drug Name
text
Dose
integer
Unit
text
Frequency
text
Route
text
Taken Prior to Study?
boolean
Start Date
date
Stop Date
date
Ongoing Medication?
boolean
Reason for Medication
text
SECTION 9: Drug Details
Only if applicable
date
if applicable
float
Dosage reduction
text
Start Date Investigational Product
date
Stop Date Investigational Product
date
Dose
float
SECTION 10: Details of RELEVANT Assessments
SECTION 11 Narrative Remarks
comment SAE
text
Investigator signature
text
Investigator name
text
Date
date
Pregnancy information
Death
Date of Death
date
Cause of Death
text
Cause of Death Specification
text
Study Conclusion
Date of subject completion or withdrawal
date
withdrawn
boolean
If Yes, tick the primary reason for withdrawal
text
Investigator comment log
Investigators Signature